Tyme Technologies, JAF announce sarcoma treatment collaboration
Tyme Technologies announced that it is collaborating with The Joseph Ahmed Foundation to provide treatment for metastatic sarcomas. The collaboration will focus on children and young adults with bone or soft tissue sarcomas, with an initial focus on Ewing's sarcoma. Sarcomas are rare forms of cancer that have poor prognosis at the metastatic stage, with most treatment options demonstrating limited efficacy and high toxicity. Two Ewing's sarcoma patients have previously been treated with Tyme's SM-88 therapy under compassionate use programs, both of whom achieved a complete or partial response with no drug-related severe adverse events. Under this new collaboration, Tyme will supply SM-88 at no cost and JAF will provide resources for physicians to perform investigator-sponsored trials. JAF and Tyme will be also participating in the April 2018 New Jersey marathon in honor of Joe's Cure Walk and to raise money for sarcoma research.